Texto: 
- BCVA: 20/20 -2 OU   (low myope OU)

- color vision (PIP): 10/14 OD  11/14 OS

- red desaturation: 90% OD

- white light brightness: 75% OD

- pupils: 4->3mm OU,    2+ APD OD

- Motility: FD & V OU

- Visual Fields: gross defect to confrontation 7-9 clock hours OD; full OS

- IOP: 16 OU

- SLE: normal anterior segment OU

- DFE: 
     Lens/vitreous: clear OU 
     macula: +FLR, flat and unremarkable OU
     A/V:
        normal caliber w/o nicking, tortuosity,                     
        attenuation, or sheathing OU
     Periphery: 
        flat and unremarkable OU
     Disc: 
        0.1 C/D OU w/o pallor/heme
        slightly increased fullness/elevation OD, but      
        sharp disc margins/clearly-defined vessels
        single flat, hypopigmented lesion just inferior   
        to disc margin OD (1/5 DD)
- Trans-sphenoidal surgical debulking (uncomplicated)

- Serology:
     Bartonella
     Lyme
     RPR/FTA

- MRI orbits
Presumably new-onset, painless, diffuse R monocular field loss  w/ +APD and subtle abnormalities of R optic disc
Large intrasellar and suprasellar mass lesion
Pituitary macroadenoma - Null Cell (non-secreting)
-Optic nerve disease:
     neuropathy: compressive/infiltrative,     
     inflammatory, ischemic, toxic
     optic nerve drusen

- Retrobulbar optic neuritis 

- Neuroretinitis (Bartonella, Syphilis, Lyme)

-Intracranial Process:
     - mass (pit adenoma, meningioma, glioma,      
     craniopharygioma)
     - aneurysm (most likely ICA)
     inflammation (sarcoid, MS)

- Retinal Dystrophy/Degeneration:
     - fundus flavimaculatus
21 y.o. woman reservist, activated & deployed into Iraq in March.

Air evacuated to Germany and then subsequently to WRAMC in mid July for dyspnea.

Pulmonology evaluation made a diagnosis of asthma, and she was started on PO steroid burst w/ taper, albuterol, Advair and Singulaire.  

R-sided visual loss (OD) started shortly after initiating these asthma meds and remained stable over next 1-2 weeks.  She then reported ‚ÄúI can‚Äôt see person standing to my right‚Äù. 

She denied any sudden onset - but is unable to pinpoint the moment when her symptoms began nor recall what she was doing; no ‚Äúfalling curtain‚Äù.

- no central vision loss OU

- no vision changes OS

- no floaters, photopsia or amaurosis 

- no headache, eye pain or photophobia 

- no gross neurologic symptoms (diplopia, dysarthria, weakness, parasthesias, confusion)

- PMH/PSH: 
     recent asthma dx

- FH: 
     non-contributory

- Social Hx:
     no tobacco/rare EtOH
     1 previous sexual partner 2 years ago

- Meds:
     PO Prednisone taper (currently 20mg qd)
     Albuterol
     Singular
     Advair
     OCP 

-Allergies: 
     PCN
- 10-15% of all intracranial tumors
- normal volunteers had 10% incidence of asymptomatic adenomas by MRI

- Found in 1.5-27% of autopsy cases

Patients present with either:
     Hormonal abnormalities
     Symptoms of compressive lesion: headache, field    
     defects or cranial nerve palsies (cavernous sinus  
     invasion) 

Genetic Association:
     MEN type 1: 
          30% of patients have pit adenoma
          Triad with parathyroid and pancreatic islet           
          tumors
     GSP:
          Gene that encodes alpha-subunit of     
          GTP-binding protein Gs
          mutation leads to activation of cAMP
     Present in:
          40% of GH-secretors
          10% of null cell (non-secretors)
          6% of ACTH-secretors

Classification:
     Based on size:
          Macroadenoma > 1cm
          Microadenoma < 1cm
     Based on what the tumor secretes:
          Prolactin, gonadotropin, GH, ACTH, TSH
          nothin‚Äô (null cell)

Surgery:
     For most non-prolactin secreting adenomas
     Usually trans-sphenoidal:
          Mortality <1%
          Common complications: nasal septal            
          perforation, ant. pit insufficiency,  
          transient diabetes insipidus, CSF leak
          Carotid injury and vision loss are RARE

     Success measures clinically and radiographically
     Normalization of hormones varies with type/size of   
     tumor
     Normalization of visual fields = 16-53%
     Improvement of visual fields = 26-70%

Treatment of Prolactinomas:
     MEDICAL (dopamine agonists)
     - PRL secretion inhibited by dopamine secretion  
     from the hypothalamus

     - Decreases tumor size      (70-90% of cases)
     - Normalizes PRL levels     (70-90% of cases)
     - Restores ovulation/menses (70-90% of cases)
     - Improves visual fields    (70-90% of cases)

     "REVERSIBLE, therefore lifelong tx is RULE"

Drugs:
     Bromocriptine (classic‚Äîused for decades)
     Side effects: N/V, dizziness, postural    
     hypotension, HA‚Äôs

Newer agents:
     Lisuride
     Pergolide
     Cabergoline

New txs for non-PRL adenomas:
     GH-secretors:
          Somatostatin analogs: octreotide & lanreotide
          Reduce GH levels in 90% of pts 
          achieve complete suppression in 50% of pts

Radiation:
     Usually reserved for residual dz or recurrence   
     after surgery
     Average total dose = 45-50 Gy
     Control rates of 85-95% @ 10 years

3 types:
     Standard
     Stereotactic fractionated
     Stereotactic radiosurgery (single dose / Gamma     
     knife)

Disadvantages:
      Slower reversal of neurologic symptoms
      Slower drop in hormonal levels
      Hypopituitarism: 50% of pts will have at least     
      one pit hormone deficiency @ 5 yrs       lifelong   
      follow-up
Secondary brain tumor:
      Risk of 1.3-1.7% @ 10 yrs
      Risk of 1.9-2.7% @ 20 yrs
      (relative risk of 9.3-16 X general population)
      Radiation-induced optic neuropathy/retinopathy
      Low risk: 0.7-2%

SRS(stereotactic radiosurgery)
       Quicker drop in hormone levels
       Adverse CNS effects in 28% of cases at 3 yrs    
       compared with 0% with FSRT3

       "NOT RECOMMENDED !!"


Keywords: 
\-\ rare\\ etoh\\ 1\\ previous\\ sexual\\ partner\\ 2\\ years\\ ago\ \(0\)\
\-\ diffuse\\ r\\ monocular\\ field\\ loss\\ w\ \(0\)\
\-\ binding\\ protein\\ gs\\ mutation\\ leads\ \(0\)\
\-\ lisuride\\ pergolide\\ cabergoline\\ new\\ txs\ \(0\)\
\-\ least\\ one\\ pit\\ hormone\\ deficiency\ \(0\)\
\-\ hormone\\ levels\\ adverse\\ cns\\ effects\ \(0\)\
\-\ standard\\ stereotactic\\ fractionated\\ stereotactic\\ radiosurgery\ \(0\)\
\-\ r\\ optic\\ disc\\ large\\ intrasellar\ \(0\)\
\-\ suprasellar\\ mass\\ lesion\\ pituitary\\ macroadenoma\ \(0\)\
\-\ rare\\ success\\ measures\\ clinically\ \(0\)\
\-\ heme\\ slightly\\ increased\\ fullness\ \(0\)\
\-\ csf\\ leak\\ carotid\\ injury\ \(0\)\
\-\ 10\\ years\\ 3\\ types\ \(0\)\
\-\ prolactin\\ secreting\\ adenomas\\ usually\\ trans\ \(0\)\
\-\ po\\ steroid\\ burst\\ w\ \(0\)\
\-\ pancreatic\\ islet\\ tumors\\ gsp\ \(0\)\
\-\ mri\\ orbits\\ presumably\\ new\ \(0\)\
\-\ toxic\\ optic\\ nerve\\ drusen\ \(0\)\
\-\ 4\\ \\-\\>\\ 3mm\\ ou\ \(0\)\
\-\ 50\\ gy\\ control\\ rates\ \(0\)\
\-\ pts\\ achieve\\ complete\\ suppression\ \(0\)\
\-\ 16\\ x\\ general\\ population\ \(0\)\
\-\ lanreotide\\ reduce\\ gh\\ levels\ \(0\)\
\-\ \\‚\\Ä\\ú\\ falling\\ curtain\\ \\‚\\Ä\\ù\\.\ \(0\)\
\-\ normal\\ anterior\\ segment\\ ou\ \(0\)\
\-\ surgery\\ average\\ total\\ dose\ \(0\)\
\-\ defined\\ vessels\\ single\\ flat\ \(0\)\
\-\ central\\ vision\\ loss\\ ou\ \(0\)\
\-\ albuterol\\ singular\\ advair\\ ocp\ \(0\)\
\-\ 9\\ clock\\ hours\\ od\ \(0\)\
\-\ 5\\ yrs\\ lifelong\\ follow\ \(0\)\
\-\ neurologic\\ symptoms\\ slower\\ drop\ \(0\)\
\-\ autopsy\\ cases\\ patients\\ present\ \(0\)\
\-\ optic\\ nerve\\ disease\ \(0\)\
\-\ normal\\ caliber\\ w\ \(1\)\
\-\ hormonal\\ levels\\ hypopituitarism\ \(0\)\
\-\ retrobulbar\\ optic\\ neuritis\ \(0\)\
\-\ therefore\\ lifelong\\ tx\ \(1\)\
\-\ sharp\\ disc\\ margins\ \(1\)\
\-\ sided\\ visual\\ loss\ \(1\)\
\-\ normalizes\\ prl\\ levels\ \(0\)\
\-\ cranial\\ nerve\\ palsies\ \(5\)\
\-\ white\\ light\\ brightness\ \(1\)\
\-\ transient\\ diabetes\\ insipidus\ \(1\)\
\-\ see\\ person\\ standing\ \(1\)\
\-\ pulmonology\\ evaluation\\ made\ \(0\)\
\-\ nasal\\ septal\\ perforation\ \(0\)\
\-\ gross\\ neurologic\\ symptoms\ \(1\)\
\-\ fundus\\ flavimaculatus\\ 21\ \(0\)\
\-\ disc\\ margin\\ od\ \(0\)\
\-\ currently\\ 20mg\\ qd\ \(1\)\
\-\ classic\\ \\‚\\Ä\\î\\ used\ \(0\)\
\-\ cavernous\\ sinus\\ invasion\ \(0\)\
\-\ unremarkable\\ ou\\ disc\ \(0\)\
\-\ sheathing\\ ou\\ periphery\ \(0\)\
\-\ low\\ myope\\ ou\ \(0\)\
\-\ clear\\ ou\\ macula\ \(0\)\
\-\ 3\\ yrs\\ compared\ \(0\)\
\-\ pip\\ \\)\\:\\ 10\ \(0\)\
\-\ induced\\ optic\\ neuropathy\ \(1\)\
\-\ secondary\\ brain\\ tumor\ \(0\)\
\-\ po\\ prednisone\\ taper\ \(0\)\
\-\ pit\\ adenoma\\ triad\ \(0\)\
\-\ hormonal\\ abnormalities\\ symptoms\ \(0\)\
\-\ men\\ type\\ 1\ \(0\)\
\-\ retinopathy\\ low\\ risk\ \(0\)\
\-\ prl\\ secretion\\ inhibited\ \(0\)\
\-\ improves\\ visual\\ fields\ \(0\)\
\-\ vision\\ changes\\ os\ \(0\)\
\-\ tsh\\ nothin\\ \\‚\\Ä\\ô\ \(0\)\
\-\ sphenoidal\\ surgical\\ debulking\ \(1\)\
\-\ recent\\ asthma\\ dx\ \(1\)\
\-\ 14\\ od\\ 11\ \(0\)\
\-\ 10\\ yrs\\ risk\ \(0\)\
\-\ stereotactic\\ radiosurgery\ \(5\)\
\-\ decreases\\ tumor\\ size\ \(0\)\
\-\ bartonella\\ lyme\\ rpr\ \(0\)\
\-\ ou\\ w\ \(5\)\
\-\ vision\\ loss\ \(11\)\
\-\ 2\\ ou\ \(4\)\
\-\ single\\ dose\ \(1\)\
\-\ field\\ defects\ \(7\)\
\-\ prl\\ adenomas\ \(0\)\
\-\ usually\\ reserved\ \(3\)\
\-\ side\\ effects\ \(7\)\
\-\ pit\\ adenoma\ \(2\)\
\-\ 2\\ weeks\ \(122\)\
\-\ next\\ 1\ \(4\)\
\-\ 1\\ c\ \(165\)\
\-\ unremarkable\\ ou\ \(0\)\
\-\ 16\\ ou\ \(0\)\
\-\ visual\\ fields\ \(16\)\
\-\ symptoms\\ began\ \(4\)\
\-\ slower\\ reversal\ \(0\)\
\-\ right\\ \\‚\\Ä\\ù\\.\ \(0\)\
\-\ reported\\ \\‚\\Ä\\ú\ \(1\)\
\-\ quicker\\ drop\ \(0\)\
\-\ pit\\ insufficiency\ \(1\)\
\-\ normal\\ volunteers\ \(1\)\
\-\ intracranial\\ tumors\ \(10\)\
\-\ hypopigmented\\ lesion\ \(3\)\
\-\ camp\\ present\ \(0\)\
\-\ asymptomatic\\ adenomas\ \(1\)\
\-\ 14\\ os\ \(0\)\
\-\ color\\ vision\ \(2\)\
\-\ tumor\\ secretes\ \(1\)\
\-\ tumor\\ normalization\ \(0\)\
\-\ subtle\\ abnormalities\ \(1\)\
\-\ gross\\ defect\ \(1\)\
\-\ elevation\\ od\ \(0\)\
\-\ dopamine\\ secretion\ \(1\)\
\-\ compressive\\ lesion\ \(3\)\
\-\ 20\\ yrs\ \(2\)\
\-\ v\\ ou\ \(0\)\
\-\ full\\ os\ \(0\)\
\-\ 5\\ dd\ \(0\)\
\-\ secretors\\ 10\ \(0\)\
\-\ relative\\ risk\ \(2\)\
\-\ woman\\ reservist\ \(1\)\
\-\ somatostatin\\ analogs\ \(2\)\
\-\ social\\ hx\ \(0\)\
\-\ retinal\\ dystrophy\ \(0\)\
\-\ restores\\ ovulation\ \(0\)\
\-\ residual\\ dz\ \(1\)\
\-\ remained\\ stable\ \(14\)\
\-\ red\\ desaturation\ \(1\)\
\-\ recommended\\ \\!\\!\\"\ \(0\)\
\-\ radiographically\\ normalization\ \(0\)\
\-\ r\ \(387594\)\
\-\ postural\\ hypotension\ \(0\)\
\-\ null\\ cell\ \(3\)\
\-\ newer\\ agents\ \(0\)\
\-\ mid\\ july\ \(0\)\
\-\ likely\\ ica\ \(0\)\
\-\ intracranial\\ process\ \(0\)\
\-\ hormones\\ varies\ \(1\)\
\-\ ha\\ \\‚\\Ä\\ô\ \(0\)\
\-\ genetic\\ association\ \(0\)\
\-\ gamma\\ knife\ \(19\)\
\-\ eye\\ pain\ \(17\)\
\-\ encodes\\ alpha\ \(1\)\
\-\ dopamine\\ agonists\ \(1\)\
\-\ common\\ complications\ \(4\)\
\-\ apd\\ od\ \(0\)\
\-\ air\\ evacuated\ \(1\)\
\-\ 1cm\\ microadenoma\ \(0\)\
\-\ pts\\ radiation\ \(0\)\
\-\ secretors\\ classification\ \(0\)\
\-\ sudden\\ onset\ \(81\)\
\-\ started\\ shortly\ \(1\)\
\-\ confrontation\\ 7\ \(1\)\
\-\ asthma\\ meds\ \(1\)\
\-\ 2\ \(13754\)\
\-\ 1cm\\ based\ \(0\)\
\-\ 1\ \(15898\)\
\-\ trans\ \(1089\)\
\-\ secreting\ \(18\)\
\-\ prolactin\ \(23\)\
\-\ mass\ \(4930\)\
\-\ macroadenoma\ \(34\)\
\-\ 3\ \(8405\)\
\-\ 10\ \(1995\)\
\-\ surgery\ \(977\)\
\-\ patients\ \(1247\)\
\-\ od\ \(7356\)\
\-\ mri\ \(5\)\
\-\ gh\ \(14320\)\
\-\ flat\ \(213\)\
\-\ cases\ \(536\)\
\-\ albuterol\ \(12\)\
\-\ advair\ \(1\)\
\-\ 9\ \(4978\)\
\-\ 50\ \(678\)\
\-\ pts\ \(61\)\
\-\ 5\ \(8237\)\
\-\ 16\ \(559\)\
\-\ risk\ \(497\)\
\-\ \\‚\\Ä\\ô\ \(1174\)\
\-\ type\ \(681\)\
\-\ taper\ \(44\)\
\-\ sphenoidal\ \(18\)\
\-\ size\ \(626\)\
\-\ neuropathy\ \(78\)\
\-\ lyme\ \(8\)\
\-\ bartonella\ \(0\)\
\-\ asthma\ \(67\)\
\-\ secretors\ \(4\)\
\-\ v\ \(54359\)\
\-\ started\ \(180\)\
\-\ radiation\ \(402\)\
\-\ onset\ \(516\)\
\-\ meds\ \(54\)\
\-\ compressive\ \(42\)\
\-\ based\ \(311\)\
\-\ apd\ \(0\)\
\-\ 7\ \(4391\)\
\-\ 20\ \(2416\)\
\-\ wramc\ \(0\)\
\-\ weakness\ \(418\)\
\-\ vitreous\ \(9\)\
\-\ uncomplicated\ \(53\)\
\-\ unable\ \(119\)\
\-\ treatment\ \(1387\)\
\-\ tortuosity\ \(14\)\
\-\ tobacco\ \(43\)\
\-\ syphilis\ \(15\)\
\-\ subunit\ \(5\)\
\-\ subsequently\ \(134\)\
\-\ srs\ \(0\)\
\-\ sle\ \(181\)\
\-\ singulaire\ \(0\)\
\-\ serology\ \(7\)\
\-\ sarcoid\ \(163\)\
\-\ rule\ \(304\)\
\-\ reversible\ \(28\)\
\-\ recurrence\ \(184\)\
\-\ recall\ \(36\)\
\-\ pupils\ \(25\)\
\-\ psh\ \(2\)\
\-\ prolactinomas\ \(1\)\
\-\ pmh\ \(2\)\
\-\ pinpoint\ \(4\)\
\-\ photopsia\ \(1\)\
\-\ photophobia\ \(28\)\
\-\ pcn\ \(0\)\
\-\ parathyroid\ \(188\)\
\-\ parasthesias\ \(8\)\
\-\ pallor\ \(12\)\
\-\ painless\ \(90\)\
\-\ octreotide\ \(9\)\
\-\ non\ \(1889\)\
\-\ nicking\ \(1\)\
\-\ neuroretinitis\ \(0\)\
\-\ n\ \(427216\)\
\-\ ms\ \(3148\)\
\-\ motility\ \(18\)\
\-\ mortality\ \(71\)\
\-\ moment\ \(6\)\
\-\ menses\ \(25\)\
\-\ meningioma\ \(167\)\
\-\ medical\ \(486\)\
\-\ march\ \(6\)\
\-\ lens\ \(6\)\
\-\ ischemic\ \(107\)\
\-\ iraq\ \(0\)\
\-\ iop\ \(1148\)\
\-\ initiating\ \(5\)\
\-\ inflammatory\ \(375\)\
\-\ inflammation\ \(200\)\
\-\ infiltrative\ \(29\)\
\-\ inferior\ \(587\)\
\-\ incidence\ \(147\)\
\-\ improvement\ \(160\)\
\-\ hypothalamus\ \(20\)\
\-\ headache\ \(722\)\
\-\ gtp\ \(0\)\
\-\ gonadotropin\ \(8\)\
\-\ glioma\ \(339\)\
\-\ germany\ \(0\)\
\-\ gene\ \(1679\)\
\-\ fta\ \(4\)\
\-\ fsrt3\ \(0\)\
\-\ found\ \(632\)\
\-\ flr\ \(0\)\
\-\ floaters\ \(1\)\
\-\ fh\ \(5\)\
\-\ fd\ \(3\)\
\-\ either\ \(202\)\
\-\ dyspnea\ \(130\)\
\-\ dysarthria\ \(21\)\
\-\ drugs\ \(60\)\
\-\ dizziness\ \(85\)\
\-\ disadvantages\ \(3\)\
\-\ diplopia\ \(50\)\
\-\ diagnosis\ \(1295\)\
\-\ dfe\ \(1\)\
\-\ deployed\ \(25\)\
\-\ denied\ \(122\)\
\-\ degeneration\ \(122\)\
\-\ decades\ \(30\)\
\-\ craniopharygioma\ \(1\)\
\-\ contributory\ \(469\)\
\-\ confusion\ \(42\)\
\-\ clearly\ \(92\)\
\-\ bromocriptine\ \(5\)\
\-\ bcva\ \(0\)\
\-\ attenuation\ \(318\)\
\-\ ant\ \(7085\)\
\-\ aneurysm\ \(644\)\
\-\ amaurosis\ \(1\)\
\-\ allergies\ \(23\)\
\-\ activation\ \(14\)\
\-\ activated\ \(8\)\
\-\ acth\ \(0\)\
\-\ 95\ \(206\)\
\-\ 90\ \(326\)\
\-\ 85\ \(172\)\
\-\ 75\ \(204\)\
\-\ 70\ \(283\)\
\-\ 6\ \(5312\)\
\-\ 53\ \(157\)\
\-\ 45\ \(319\)\
\-\ 40\ \(508\)\
\-\ 30\ \(631\)\
\-\ 28\ \(276\)\
\-\ 27\ \(323\)\
\-\ 26\ \(318\)\
\-\ 15\ \(862\)\
\-\ 0\ \(11370\)\
